Belatacept Removal by Plasmapheresis: Dose Adjustments and Clinical Recommendations
Sign Up to like & getrecommendations! Published in 2024 at "Transplantation Direct"
DOI: 10.1097/txd.0000000000001677
Abstract: B elatacept, a fusion protein immunosuppressant, may be removed by plasmapheresis (PP) in a clinically significant amount. Scenarios arise requiring concurrent PP in patients maintained on belatacept; however, clinical guidance for dosing remains an unmet… read more here.
Keywords: adjustments clinical; dose adjustments; removal plasmapheresis; belatacept removal ... See more keywords